Key facts
- Ouro Medicines’s last known valuation is $1.7B (Mar 2026).
- It has raised $120.0M; the latest was Merger/Acquisition ($1.7B) in Mar 2026.
- Notable investors include New Enterprise Associates, Norwest, Boyu Capital, UPMC Enterprises, Boai Wanwu (Shanghai) Venture Capital Management — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Ouro Medicines
- ·The full record, as it builds
Funding rounds
No funding rounds for Ouro Medicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ouro Medicines
Developer of innovative therapeutics designed to treat immune-mediated diseases by targeting underlying immune system dysfunction. The company offers a research-driven pipeline, advanced scientific capabilities in immune modulation, integrated discovery and development processes, and a focused approach to creating targeted therapies with validated outcomes, enabling patients with immune-mediated conditions to receive more precise and effective treatment options.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2024
- Employees
- 25
- Website
- ouromedicines.com/
- Ownership
- Privately Held (backing)
Ouro Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ouro Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ouro Medicines in its N-PORT filings yet. We sweep new filings monthly.